<DOC>
	<DOCNO>NCT02588053</DOCNO>
	<brief_summary>Primary Aims : To determine effective long term Natalizumab ( NTZ ) therapy slow progression whole brain atrophy . Whole brain atrophy rate measure magnetic resonance imaging ( MRI ) scan compare patient Multiple Sclerosis ( MS ) use NTZ least 2 year versus age gender-matched healthy control . The primary outcome whole brain atrophy rate measure percent change brain volume ( PBVC ) two-year period . Primary hypothesis : The investigator hypothesize long term ( &gt; 2 year ) NTZ therapy slow rate whole brain atrophy patient Multiple Sclerosis ( MS ) ( measure percent change brain volume ) , reach whole brain atrophy rate similar non-MS control ( true `` disease activity free '' state ) .</brief_summary>
	<brief_title>Does Long-Term Natalizumab ( NTZ ) Therapy Normalize Brain Atrophy Rates Quality Life ( QOL ) Relapsing Remitting Multiple Sclerosis ( RRMS ) ?</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>1855 inclusive year age time inform consent Diagnosis relapse multiple sclerosis define 2010 revise McDonald criterion Currently take Tysabri Systemic steroid user comorbidities could confound MRI outcome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>